In In re Abbott Diabetes Care Inc., Nos. 11-1516, -1517 (Fed. Cir. Sept. 28, 2012), the Federal Circuit vacated-in-part the Board’s final rejection of numerous claims in the ex parte reexamination of U.S. Patent Nos. 6,175,752 ("the ’752 patent") and 6,565,509 ("the ’509 patent") due to the Board’s unreasonably broad claim construction.